Reporte zur Charge U7675DC

Symptomtext

received doses of menactra in 2017, 11NOV2020, extra dose vaccine menquadfi on 31JUL2023 with no reported AE; Initial information received on 01-Aug-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 18 years old female patient who received doses of menactra in 2017, 11NOV2020, extra dose vaccine menquadfi on 31JUL2023 with no reported adverse event. The patient's past vaccination(s) included menactra in 2017 and on 11-Nov-2020. The patient's past medical history, medical treatment(s) and family history were not provided. Concomitant medications included meningococcal vaccine B RFHBP/NADA/NHBA OMV (Bexsero) for Immunisation. On 31-Jul-2023, the patient received a dose 3 of suspect meningococcal A-C-Y-W135 (T CONJ) vaccine, Solution for injection lot U7675DC, expiry date:30-Sep-2025 via intramuscular route in the left deltoid for prophylactic vaccination (strength, dose: unknown), received doses of menactra in 2017, 11NOV2020, extra dose vaccine menquadfi on 31JUL2023 with no reported adverse event (extra dose administered) (latency same day). Action taken: not applicable. Reportedly, patient had previously received doses of MENACTRA in 2017 and on 11NOV2020. The patient received a third dose of MENQUADFI on 31JUL2023. The dose of MENQUADFI was administered 2 years and 8 months after the last dose of MENACTRA At time of reporting, the outcome was Unknown for the event extra dose administered. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.